Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological studies performed in 19 patients before and at the end of this treatment period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumor size was observed, and in 3 cases an important shrinkage was documented. At surgery, the adenoma-.: tous tissue appeared softer than in nonpretreated patients, facilitating the operation. Pathological examination revealed widening of perivascular spaces with accumulation of fibrous tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologi-:; tally pronounced cell involution as observed in prolactin-producing adenomas treated with dopamine agonists. No significant difference in frequency or extent of cellular changes was 9 noted between the two groups. These morphological findings seem to be more consistent with a functional inhibition of growth hormone release than with cellular alterations induced by octreotide. Endocr Pathol 2" 123-131, 1991, 9 L
Although natural somatostatin strongly inhibits growth hormone (GH) secretion, it could not be used successfully in the treatment of acromegaly due to its short half-life and because of the rebound secretion of GH after cessation of the infusion [6] . Recently, a new somatostatin analog, octreotide (Sandostatin, Sandoz Ltd., Basel, Switzerland), with a marked and prolonged inhibitory effect on GH secretion, became available for clinical use [5, 13, 15] . In this article, we report data recorded from 24 acromegalic patients treated with octreotide before transsphenoidal surgery. Radiological evolution and appearance of the adenoma at surgery are reviewed. Special attention is given to possible morphological changes induced by octreotide.
Materials and Methods
This series includes 24 acromegalic patients (13 men and 11 women, aged 28-63 years). Diagnosis of acromegaly was made clinically and was confirmed biochemically by elevated serum GH and plasma insulinlike growth factor I (IGF-I) concentrations and radiologically by demonstration of a pituitary tumor by computed tomography (CT) scanning or magnetic resonance imaging (MRI). Pertinent clinical data are reported in Table 1 .
Octreotide was given at a constant dose of 3 x t00 Ixg/day subcutaneously for 3 to 6 weeks before transsphenoidal surgery in 12 patients (group I, cases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Twelve patients (group II, cases 13-24) were treated for 6 months before surgery. In this group, the Pronounced  II  Pronounced  II  Slight  II  NC  II  NC  II  Slight  III  NC  III  None  III  NC  III-A NC B = bromocriptine; R = radiotherapy; S = surgery; NC = no control. 8  Soft  10  Liquid  10  Soft  12  Soft  14  Soft  14  Soft  15  Soft with fibrous septa  16  Soft  14  Soft  16  Soft  t6 Soft with hard peel 23 Firm dose ofoctreotide was augmented to 3 x 500 lag/day when a decrease in therapeutic effect was experienced, as expressed by a loss of inhibition of GH and IGF-I secretion. The last injection was given in each case 4 hours before surgery. The study was approved by the local ethical committee. The purpose of the study was explained to the patients, who gave their oral consent.
Radiological Study
The pituitary region was evaluated by CT scanning using a Siemens Somatom 2N or by MRI using a Siemens Magnetom before octreotide treatment and after 3 weeks in group I and after 6 months in group II. Grading and suprasellar extension were assessed as previously described [11, 22] . The largest diameter of the cavity was also measured after adenomectomy.
Morphological Study
For light microscopy, small pieces of tumor tissue were fixed in Bouin's solution, dehydrated in a series of graded ethanols, and embedded in paraffin. Sections were stained For immnnocytochemistry, the PAP technique was used [20] . Paraffin sections of 4-to 6-1~m thickness were immunostained for GH, prolactin (PP, L), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH). Dilution of primary antibodies varied from 100 to 640; duration of exposure to the primary antibody was 30 minutes. Negative controls were performed by incubating the sections with the same dilutions of normal rabbit serum as were employed for the corresponding specific antiserum.
For electron microscopy, small parts of tumor tissue were fixed in 4% glutaraldehyde, osmicated, dehydrated, and embedded in Epon. Ultrathin sections were stained with uranyl acetate and lead citrate and investigated with a Philips 410-LS electron microscope.
Results
In group I, octreotide treatment resulted in clinical improvement and a marked reduction of serum GH and plasma IGF-I concentrations, except ill 1 case (case 12). In group II, tile initial inhibition of GH and IGF-I secretion with 3 x 100 lxg octreotide was only retained in 3 cases (13, 15, 16) , whereas in 4 cases (18, 20, 22, 23 ) the same therapeutic effect was retrieved by increasing the dose. In 5 cases (14, 17, 19, 21, 24) , the increase of the octreotide dose to 3 • 500 Ixg could not correct the progressive hormonal deterioration but still maintained GH and IGF-I levels below" pretreatment values.
Radiological Data
In group I, no change in tumor size was observed in 6 cases after 3 weeks of treatment (see Table 1 ). In 5 cases, a slight reduction could be seen, and in 1 case marked shrinkage was observed. In group II, no changes were observed after 6 months of treatment in 2 cases, whereas 3 tumors showed a slight regression and 2 others were markedly smaller.
Surgical Data
In group I, the adenomatous tissue appeared soft or hemorrhagic in 9 cases (see Table 1 ). In 2 cases it was firm and in 1 case fibrotic. In the latter case (12) surgical excision could not be achieved completely. In group II, the adenoma had a soft consistency in 10 cases, was liquid in 1 case, and was firm in another case.
Morphological Data
The data on cases 9 and 12 should be interpreted with care, since these patients formerly underwent pituitary radiotherapy or surgery, which could modify the morphological features of the adenoma. Five patients received bromocriptine, but it is improbable that the morphological changes were induced by this treatment, since it was stopped at least 2 months prior to the octreotide administration.
By light microscopy on hematoxylineosin-stained slides, the tumors of group I were found to be partly acidophilie and partly chromophobic adenomas, exhibiting a diffuse pattern with some variation in cellularity, slight to moderate cellular and nuclear pleomorphism, and occasional mitotic figures Table 2 ). With the exception of I case (9) in which acum hemorrhagic infarction was evident, the adenoma cells showed neither necrosis nor damage; the architecture was preserved. The capillaries showed no abnormalities; no capillary occlusion, thrombosis, or endothelial cell injury was identified. In 5 cases, minimal or slight perivascular fibrosis was noted with widening of perivascular spaces, and in 1 case (12) the fibrosis was massive. No inflammatory infiltration was evident. In I case (8) , the adenoma cells were interspersed with nerve fibers and large cells possessing long cytoplasmic processes and a granular cytoplasm resembt}ng nerve cells. Neural tissue was revealed in one area adjacent m the adenoma. This lesion associated with the somatotroph adenoma was regarded as representing an adenohypophyseal neuronal choristoma similar to those described elsewhere [1, 18] . No striking differences were found in group II (Table 3) . One adenoma showed signs of necrosis (case 22). Five adenomas showed mild, mainly perivascular fibrosis.
By immunocytochemistry, the adenoma cells showed varying degrees ofpositivity for GH. Immunoreactivity varied from case to case and even from area to area within the same tumor. The number of adenoma cells showing GH immunoreactivity was not counted. Based on nonquantitative evaluation, adenoma cells with GH immunostaining were regarded as being between 10 and 90% of the total population in the various tumors. In 5 tumors from group I and 1 tumor from group II, scattered cells (tess than 10% of the cell population) yielded PRL immunoreactivity. The PRL immunoreactivit,/was more pronounced in one adenoma of group II. Immunostainings for LH, FSH, TSH, and ACTH were negative in all adenomas.
By electron microscopy, the tumors of group I showed the characteristic features of somatotroph adenomas (see Table 2 ). In 7 cases the adenomas were densely granulated, in 4 adenomas the secretory granules were sparse, and in 1 case (12) the tumor was composed of both densely and sparsely granulated cells. Eleven tumors consisted of cells exhibiting the ultrastructural features of somatotrophs, whereas 1 tumor (case 1) was composed ofmammosomatotrophs. In I case (8) in which the adenoma was interspersed with nerve cells, as seen by histology, the neural components were not recognized in the available electron microscopical specimens. In the case with acute infarction (case 9), the adenoma cells showed signs of advanced necrosis with nuclear pyknosis, clumping ofchromatin, chromatotysis, multifocal disruption of the nuclear membrane, vesiculation of the endoplasmic reticulum, and marked dilation of the Golgi complex. The mitochondria were swollen and had lost their internal compartments and, in some places, cell membranes were discontinuous. No cell damage was identified in the remaining 11 tumors. The nuclei and cell membranes appeared to be normal. In 10 tumors, cell size and nuclear size did not seem to differ considerably from control cases, whereas in 2 cases (3, 12) , cell and nuclear sizes appeared to be decreased. The nuclei had normal features. The endoptasmic reticulum membranes were conspicuous and wellpreserved. The Golgi complexes were prominent and consisted of sacculi and sacs containing immature secretory granules. The fibrous bodies, a characteristic feature of sparsely granulated GH cell adenomas [12] were noticeable without differing in size, number, and ultrastructural appearance from those seen in untreated somatotroph adenomas. The mitochondria were ovoid or rod-shaped and had tubular cristae and a moderately electron-dense matrix~ The size and number of secretory granules seemed to be slightly larger and more numerous in 2 cases of densely granulated tumors (3, 4), whereas they were within the normal range in the rest of the adenomas. As considerable variation existed from one tumor to the other and even between different areas of the same tumor, and because no morphometric analysis has been performed, definite conclusions could not be drawn as to whether the size and number of secretory granules had changed during treatment with octreotide. The lysosomes in 6 cases seemed to be unusually large and coalesced, containing lipid droplets and secretory granules. Crinophagy (i.e., the uptake of secretory granules into lysosomes) was more pronounced in the adenomas of patients treated with octreotide compared to those with no octreotide medication before surgery (Fig. 1) . In 11 somatotroph adenomas, no exowtosis was observed, whereas in the mammosomatotroph adenoma, extrusion of secretory granules was common. The capillaries, in general, appeared to be normal and patent; no platelet aggregation, thrombosis, or vascular occlusions were seen. The endothelial cells showed no major alterations. In 3 cases, the perivascular space was wider than in the untreated cases; accumulation of fibroblasts and collagen fiber deposits were observed. This perivascutar fibrosis was slight to moderate in 8 tumors and absent in 3 tumors. No interstitial fibrosis was found. It is noteworthy that 4 adenomas contained endocrine amyloid.
The morphological features by electron microscopy of the adenomas from group 1I (see Table 3 ) were not significantly different from those noted in group I. Six densely granulated adenomas were observed. In 5 adenomas, the secretory granules were sparse and, in 1 case (19), the tumor was composed of both densely and sparsely granulated cells.
One densely granulated GH cell adenoma (case 14) consisted of cells that were often spherule-shaped and possessed eccentric, crescent-shaped nucleus and fibrous bodies (Fig. 2) . These findings suggest that this tumor represented an originally sparsely granulated GH cell adenoma and accumulation of secretory granules was the result of somatostatin analog treatment. Cell size seemed to be decreased in 2 cases (16, 18) . In 3 of the densely granulated adenomas (cases 13, 18, 21), unusually numerous and large secretory granules were observed. Striking accumulation of tysosomes was noted in 1 case (21). Endocrine amyloid was present in 3 adenomas (Fig. 3) .
Discussion
The suppressive activity ofoctreotide on GH secretion and its therapeutic value in the management of acromegaly are now well established [7, 8, 14] . This study was initiated to assess the effect of octreotide on volume, appearance, and morphological features of GH cell adenomas. Shrinkage of GH cell adenomas would make octreotide a useful drug to prepare patients for surgery [17] . In our series, involution was obtained in t 1 of 19 cases, but it was only significant in 3 cases. Modest reduction in tumor size in 3 of 6 patients has been reported by Barnard and colleagues [4] , whereas Ducasse and associates [9] described major regression in 1 patient treated with an infusion ofoctreotide. Barkan and co-workers [2] observed significant reduction of the tumor volume in 9 of 15 acromegalic patients. The soft consistency of the adenomatous tissue found at surgery makes the operation easier. This softening effect of octreotide was recorded in 19 of our cases and was also observed by Spinas and colleagues [19] in 5 cases. However, larger series are required to reach definitive conclusions regarding the influence of octreotide on tissue softening, shrinkage of the adenoma, and potential benefits of these effects.
The morphological response of somatotroph adenomas to octreotide was not uniform and not marked, despite the fact that the drug caused clinical improvement and substantial decrease in serum GH levels in acromegalic patients. Lysosomes were large and numerous in several cells, and crinophagy was observed, suggesting that hormone release was suppressed and the retained secretory products ofadenomatous cells were intracellularly degraded by lysosomes. Some adenomatous cells appeared to be smaller than those of untreated somatotroph adenomas and, in several tumors, varying degrees ofperivascular fibrosis was noticeable. Some tumors removed from octreotide-treated patients were, however, morphologically indistinguishable from those not exposed to octreotide. Furthermore, no morphological difference could be evidenced between ade- nomas treated ~br 3 weeks and those treated for 6 months. Also, no important difference could be detected between adenomas of patients presenting with an escape to the long-term treatment and those from patients who remained responsive. In the present series, with the exception of 2 adenomas with large areas of hemorrhagic necrosis, no cell necrosis, endothelial injury', platelet aggregation, vascular damage, or thrombosis was noted, indicating that octreotide had no direct cytotoxic or vasotoxic effects. The vascular change in the 2 exceptional cases was interpreted as an incidental finding, since hemorrhages and loci of necrosis also occur in tumors not exposed to octreotide [12] .
Our morphological results are in agreement with the literature. Landolt and Osterwalder [16] found amyloid deposits and perivascular fibrosis but no consistent ultrastructural alterations in the secretory apparatus of adenoma cells. George and colleagues [10] investigated the somatotroph adenoma of a 36-year-old acromegalic woman treated for 10 days with octreotide. These authors noted an abundance of lysosomes with crinophagy and broadening of the perivascutar space with slight fibrosis around the capillaries. Compared to 10 somatotroph adenomas not exposed to octreotide, the adenoma cells in the octreotide-treated patient appeared to be smaller and contained smaller nuclei as well as cytoplasm, and lysosomes occupied a larger area of the cytoplasmic volume. The nuclear-cytoplasmic ratio, cytoplasmic volume densities of endoplasmic reticulum, Golgi apparatus, mitochondria, and secretory granule diameters did not differ significantly from the control values. Barkan and co-workers [3] observed perivascular fibrosis and a reduction of both cytoplasmic and nuclear areas. These authors also reported 2 densely granulated adenomas with features of initially sparsely granulated adenomas, resembling the morphological appearance of i case in our series.
All these results are consistent with functional inhibition of GH release. Dopamine agonists, such as bromocriptine, cause reversible shrinkage of PRL-secreting pituitary adenomas associated with morphologically pronounced cell involution [21] . The changes are striking and are characterized by a substantial decrease in cell size and cytoplasmic and nuclear area, an increase in the nuclear-cytoplasmic ratio, and a reduction in cytoplasmic volume densities ofendoplasmic reticulum membranes and Golgi apparatus. These changes are not apparent in GHsecreting pituitary adenomas exposed to octreotide. Thus, in tumors removed from octreotide-treated patients, a discrepancy exists between functional inhibition and morphological findings. 
